Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY03003 in early-stage Parkinson's disease
NCT02055274Phase 1Completed
- Sponsor
- Luye Pharma Group
- Start
- Oct 2013
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Rotigotine extended-release microspheres in Parkinson's disease (PD) (3 arms), sponsored by Luye Pharma Group. Primary endpoint: Maximum Plasma Concentration at 5 weeks. Started Oct 2013; status: completed.
02
Drugs
Rotigotine extended-release microspheres
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02055274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02055274.